Higher gut bacteria diversity tied to slower metastatic melanoma progression

Posted by: | June 13, 2017 | Comments


The blend of bacteria in the digestive tract of metastatic melanoma patients is associated with disease progression or delay in patients treated with immunotherapy, researchers at The University of Texas MD Anderson Cancer Center report at the 2017 annual meeting of the American Society of Clinical Oncology.

Their study of fecal samples from 105 patients treated with immune checkpoint blockade indicates that certain characteristics of patients’ microbiomes correlate with slower disease progression while other qualities are associated with rapid worsening of the disease.

“Greater diversity of bacteria in the gut microbiome is associated with both a higher response rate to treatment and longer progression-free survival,” said study leader Jennifer Wargo, M.D., associate professor of Surgical Oncology at MD Anderson.

Wargo and colleagues also found that an abundance of specific bacteria also is associated with higher response rate and longer progression-free survival.

Read the Article at: Science Daily

Stay up-to-date!
Email Address *
First Name
Last Name

* indicates required
Privacy Policy

Terms & Conditions | Privacy Policy | © 2018 The Translational Microbiome Research Forum